.webp)
Share
.webp)
.webp)
.webp)
.webp)
Michel Lagarde
West Pharmaceutical Services, Inc., a global provider of innovative solutions for injectable drug administration, has appointed Michel Lagarde as President and Chief Executive Officer (CEO) and a member of the company’s Board of Directors.
He succeeds Eric M. Green, who is retiring from his positions as President, CEO, and Board Chair.
As part of the leadership transition, the Board of Directors has also elected Lead Independent Director Robert F. Friel to serve as Board Chair.
Lagarde brings extensive global leadership experience across the pharmaceutical, biotechnology, and healthcare services sectors. Most recently, he served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, where he was responsible for overseeing the majority of the company’s business operations and supporting growth across its diverse portfolio.
He joined Thermo Fisher in 2017 as Senior Vice President and President of Pharma Services following the company’s acquisition of Patheon N.V. Prior to that, he served as President and Chief Operating Officer of Patheon, where he helped drive the company’s growth as a leading pharmaceutical services provider.
Earlier in his career, Lagarde was Managing Director at JLL Partners, a private equity firm focused on healthcare services and related industries. He also spent 12 years at Philips, holding a variety of finance leadership roles across multiple international markets and gaining broad experience in global business operations.
In addition to his executive leadership experience, Lagarde serves on the Board of Directors of Vertex Pharmaceuticals, a position he has held since 2023. He currently chairs the company’s Audit and Finance Committee, contributing expertise in financial oversight and corporate governance.
Lagarde holds a Bachelor of Business Administration from European University in Antwerp, Belgium, and an Executive Master’s degree in Finance and Control from Maastricht University in the Netherlands.
His appointment marks an important leadership transition for West as the company continues to support pharmaceutical and biotechnology customers with advanced drug delivery and containment solutions while pursuing its long-term growth strategy.
